Search
Search Results
##search.searchResults.foundPlural##
-
SARS-CoV-2 INFECTED PATIENTS: FROM A HEMATOLOGIST PERSPECTIVE COVID-19 and Hematology
1136PDF: 974HTML: 345 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2865PDF: 1034HTML: 5531 -
THE CHALLENGE OF AML IN OLDER PATIENTS
2220PDF: 999HTML: 2176 -
TUBERCULOSIS IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS.
2689PDF: 973HTML: 3650 -
MOLECULAR MECHANISMS OF INHIBITOR DEVELOPMENT IN HEMOPHILIA Guest Editor: Giancarlo Costaman
3385PDF: 1630HTML: 453 -
-
ADVANCES IN THE TREATMENT OF MALARIA
2890PDF: 1317HTML: 6004 -
CLINICAL ASPECTS AND THERAPY OF SPORADIC BURKITT LYMPHOMA
1334PDF: 608HTML: 3373 -
Coronavirus disease 2019 (COVID-19) severity in patients with thalassemias: A Nationwide Iranian Experience Coronavirus in patients with thalassemias
1427PDF: 496HTML: 188 -
MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA
748PDF: 474HTML: 6274 -
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2824PDF: 1149HTML: 3299 -
LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
1664PDF: 811HTML: 871jdoe, table 2 infections CML .doc: 204jdoe, table 1 infections CML .doc: 195 -
PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?
2972PDF: 997HTML: 2068Cover letter: 187 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
4063PDF: 1561HTML: 9194Untitled: 287Untitled: 194Untitled: 179Untitled: 172Untitled: 196Untitled: 352 -
ROLE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
2075PDF: 829HTML: 1055 -
THE PROTHROMBOTIC STATE ASSOCIATED WITH SARS-COV-2 INFECTION: PATHOPHYSIOLOGICAL ASPECTS COVID and Thrombosis
2036PDF: 827HTML: 229 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1801PDF: 839HTML: 183 -
PARASITIC INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
3746PDF: 1257HTML: 3911Untitled: 239Untitled: 275 -
ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA
1421PDF: 825HTML: 947 -
FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT
4482PDF: 1660HTML: 4082Tables and Images: 246 -
WHAT ARE FUNGAL INFECTIONS?
4268PDF: 2438HTML: 27645de Pauw: 252 -
PREVALENCE OF ANEMIA, IRON DEFICIENCY, AND IRON DEFICIENCY ANEMIA AND DIAGNOSTIC PERFORMANCE OF HEMATOLOGIC AND BIOCHEMICAL MARKERS OF SIDEROPENIA IN 1- TO 5-YEAR-OLD CHILDREN IN THRACE GREECE Prevalence of ID, IDA and anemia in Greek Thrace
2058PDF: 895HTML: 294 -
ANTIFUNGAL THERAPY IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
4823PDF: 1579HTML: 2254Untitled: 229Untitled: 249Untitled: 255Untitled: 229Untitled: 236 -
INVASIVE FUNGAL INFECTION IN CHILDREN WITH ACUTE LEUKEMIA AND SEVERE APLASTIC ANEMIA IFI in Children with Acute Leukemia and SAA
2795PDF: 916HTML: 238 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3387PDF: 1382HTML: 2683 -
Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). Azacytidine failure revisited
1119PDF: 878HTML: 255 -
THE PERFORMANCE OF HOMA 2 COMPARED TO DYNAMIC MARKERS OF INSULIN SECRETION AND SENSITIVITY/RESISTANCE FOR PREDICTING DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: THE EXPERIENCE OF A SINGLE CENTRE HOMA 2 and DYNAMIC MARKERS OF INSULIN SECRETION FOR PREDICTING DYSGLYCEMIA in TDT
136PDF: 112HTML: 21 -
The MINI-POLATUZUMAB VEDOTINE PLUS CHP (POLA-R-CHP) VS. MINI-R-CHOP IN PATIENTS OVER 80 YEARS OF AGE WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, PROPENSITY SCORE-MATCHED ANALYSIS STRATIFIED BY SIMPLIFIED FRAILTY SCORE PolaRCHP vs. RCHOP for older patients
1365PDF: 442HTML: 106 -
PEDIATRIC MASTOCYTOSIS: AN UPDATE Chldren' Mastocytosis
1905HTML: 1504PDF: 1125 -
ACQUIRED REFRACTORY IRON DEFICIENCY
3493PDF: 1220HTML: 1147 -







